- Home
- CLDI vs MTVA Comparison
CLDI vs MTVA Comparison
Compare CLDI & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- MTVA
- Stock Information
- Founded
- CLDI 2014
- MTVA 2014
- Country
- CLDI United States
- MTVA United States
- Employees
- CLDI N/A
- MTVA N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- MTVA
- Sector
- CLDI Health Care
- MTVA
- Exchange
- CLDI Nasdaq
- MTVA NYSE
- Market Cap
- CLDI 14.0M
- MTVA 13.6M
- IPO Year
- CLDI N/A
- MTVA N/A
- Fundamental
- Price
- CLDI $0.48
- MTVA $0.81
- Analyst Decision
- CLDI Strong Buy
- MTVA Strong Buy
- Analyst Count
- CLDI 2
- MTVA 1
- Target Price
- CLDI $15.00
- MTVA $12.00
- AVG Volume (30 Days)
- CLDI 386.9K
- MTVA 1.4M
- Earning Date
- CLDI 05-13-2025
- MTVA 05-08-2025
- Dividend Yield
- CLDI N/A
- MTVA N/A
- EPS Growth
- CLDI N/A
- MTVA N/A
- EPS
- CLDI N/A
- MTVA N/A
- Revenue
- CLDI N/A
- MTVA N/A
- Revenue This Year
- CLDI N/A
- MTVA N/A
- Revenue Next Year
- CLDI N/A
- MTVA N/A
- P/E Ratio
- CLDI N/A
- MTVA N/A
- Revenue Growth
- CLDI N/A
- MTVA N/A
- 52 Week Low
- CLDI $0.35
- MTVA $0.71
- 52 Week High
- CLDI $4.90
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- CLDI 38.44
- MTVA N/A
- Support Level
- CLDI $0.41
- MTVA N/A
- Resistance Level
- CLDI $0.45
- MTVA N/A
- Average True Range (ATR)
- CLDI 0.07
- MTVA 0.00
- MACD
- CLDI 0.02
- MTVA 0.00
- Stochastic Oscillator
- CLDI 56.57
- MTVA 0.00
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.